Radiation therapy (RT) is the single most utilized therapeutic agent in oncology, yet advances in radiation oncology have primarily focused on beam properties. One obvious shortcoming of current clinical practice is that RT is planned without regard to any of the tumor-environmental factors that may influence outcome.
We integrate mathematical, computational, biological and clinical sciences to thoroughly investigate tumor growth and response to single or combination therapy. In close collaboration with experimentalists and clinicians, mathematical models that are parameterized with experimental and clinical data can help estimate patient-specific disease dynamics, and predict response to different treatments or treatment protocols.
Tumor-associated antigens, stress proteins, and danger-associated molecular patterns are endogenous immune adjuvants that can both initiate and continually stimulate an immune response against a tumor. In retaliation, tumors can hijack intrinsic immune regulatory programs, thereby facilitating continued growth despite an activated antitumor immune response. Clinically apparent tumors have co-evolved with the patient’s immune system and form a complex Tumor-immune ecosystem.
We combine experimental studies and clinical data to calibrate and rigorously validate mathematical and computational frameworks that simulates the complex adaptive tumor-immune interactions, and how cancer therapies change the tumor-immune ecosystem.
Despite new strategies in “precision medicine” in which the screening or specific therapy is guided by molecular biomarkers, treatment protocols rarely vary between patients. Putative biomarkers are often collected at single time points (such as a genomic profile at biopsy, or cancer stage including tumor size, lymph node involvement, and metastatic load) and are rarely predictive or prognostic.
Our group pioneers the approach to harness patient-specific dynamics as biomarkers for treatment response. With mathematical models describing biomarker dynamics over time, we can make predictions and compare and evaluate clinical responses against the prediction. This identifies actionable triggers for treatment adaptation and quantitative personalized oncology
EnderlingLab wins $50K pilot project award at the 2019 IMO workshop
The 2019 Integrated Mathematical Oncology workshop was held in November on the topic "Evolutionary Tumor Board". The team, lead by Drs. Solmaz Sahebjam, Chris Whelan, and Heiko Enderling, developed an evolutionary trap and patient-specific intermittent therapy model to help personalize therapy for recurrent high-grade glioma patients.
EnderlingLab receives R21 to predict patient-specific prostate cancer treatment responses
Intermittent androgen deprivation therapy (IADT) is a promising strategy to counteract evolution of resistance in prostate cancer patients. However, successful implementation of IADT requires identification of resistance mechanisms, prediction of responses, and determination of clinically actionable triggers of when to pause and when to resume IADT cycles.
In this work we propose to develop a mathematical framework to explore the contribution of prostate cancer stem cell dynamics to evolving resistance, and to use these dynamics in computer simulations to reliably forecast the response in subsequent treatment cycles on a per patient basis.
On the profession of Mathematical Oncology
Drs. Brady and Enderling publish an opinion article in the Bulletin of Mathematical Biology on the necessary steps for mathematical models to predict novel or optimal cancer theapies. The Brady Pipeline is published open access.
Daniel Glazar presents posters at Society for Neurooncology annual meeting
Congratulations Daniel Glazar on a successful poster presentation at the annual meeting of the Society for Neurooncology (SNO) in Phoenix, AZ.
Daniel, jointly supervised by Dr. Solmaz Sahebjam, presented his work on a novel mathematical dynamics biomarker to predict individual responses to combination therapy in recurrent high-grade glioma patients.